CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
协同的前景：局部干预与 CAR-T 细胞治疗在实体瘤中的应用
英文原题：Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.
查看英文原题
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法已在多种B细胞恶性肿瘤的治疗中确立地位。然而，由于肿瘤间及肿瘤内异质性以及免疫抑制性微环境，将这一治疗效果转化应用于实体瘤一直面临挑战。局部干预手段，如手术、放疗、局部消融和局部区域药物递送，可通过改善肿瘤浸润和降低全身毒性来增强CAR-T 细胞疗法在实体瘤中的效果。此外，消融和放疗已被证明可通过远隔效应对全身免疫应答进行（再）激活，并在物理、细胞和化学层面重编程肿瘤微环境。本综述重点阐述了联合方法克服CAR-T 细胞疗法障碍的潜在协同作用，并总结了可能为新的治疗方案铺平道路的近期研究。
展开英文摘要原文
Chimeric antigen receptor T cell therapy has been established in the treatment of various B cell malignancies.
However, translating this therapeutic effect to treat solid tumors has been challenging because of their inter-tumoral as well as intratumoral heterogeneity and immunosuppressive microenvironment. Local interventions, such as surgery, radiotherapy, local ablation, and locoregional drug delivery, can enhance chimeric antigen receptor T cell therapy in solid tumors by improving tumor infiltration and reducing systemic toxicities.
Additionally, ablation and radiotherapy have proven to (re-)activate systemic immune responses via abscopal effects and reprogram the tumor microenvironment on a physical, cellular, and chemical level. This review highlights the potential synergy of the combined approaches to overcome barriers of chimeric antigen receptor T cell therapy and summarizes recent studies that may pave the way for new treatment regimens.
论文信息
- 作者
- Holtermann A、Gislon M、Angele M、Subklewe M、von Bergwelt-Baildon M、Lauber K、Kobold S
- 第一作者单位
- Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, Lindwurmstrasse 2a, 80336, Munich, Germany.Germany
- 通讯作者单位
- Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, Lindwurmstrasse 2a, 80336, Munich, Germany. Sebastian.kobold@med.uni-muenchen.de.Germany
- 文献类型
- 综述
- 期刊
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2024 Sep
- 原文标识
- PubMed 39080180 · DOI 10.1007/s40259-024-00669-y
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →